On behalf of our investors in the Private Debt IV – Flexible fund, we are pleased to have supported Procuritas with the financing of Nordic Biomarker, a leading Swedish developer and manufacturer of reagents used for blood coagulation testing.

‍

About Nordic Biomarker

Founded in 2007, Nordic Biomarker is a developer and manufacturer of advanced reagents, calibrators and controls for lab-based blood coagulation testing, based in Umeå, Sweden. The company offers products used for a wide range of routine and specialty lab-based tests across patients’ treatment journey. Product development and production is performed in-house at Nordic Biomarker’s facilities in Sweden and distributed to end-customers via a network of distributors.

With a growing product portfolio of both routine and specialty reagents for the blood coagulation testing, Nordic Biomarker is a valued collaboration partner for its customers, supplying the healthcare sector with a high-quality product that enables precise analysis of patients’ health.

‍

MEDIA CONTACT 

If you’d like more information on this release, please contact:

Caroline Soliman, Director        

Tel: +45  3625 6144

E-mail: caroline.soliman@capital-four.com

Mikkel  Sckerl, Partner

Tel: +45  35256112

E-mail: mikkel.sckerl@capital-four.com

‍